Fowler J C
Flinders University of South Australia, Adelaide.
Australas Biotechnol. 1994 May-Jun;4(3):169-71.
Recent discoveries and innovations in DNA technology have provided scientists with the ability to rapidly identify complex organisms, or samples therefrom, by detailed study of their genes and genome. In various disciplines, most notably in human forensic identifications, parentage tests and disease diagnosis, these activities have moved to commercial practice. However the rigour of quality assurance in these and other areas has not, in general, kept pace with technological innovation in molecular diagnostics. Insufficient resources are given to objective and ongoing evaluation of the quality of molecular diagnostic services, yet sustained quality is the key to long term credibility of the industry. The rapidly expanding commercial prospects for this technology must be accompanied by a planned commitment of resources to cost efficient quality assurance programs which include both declared and undeclared trials.
DNA技术领域最近的发现和创新，使科学家能够通过对复杂生物体或其样本的基因和基因组进行详细研究，快速识别这些生物体或样本。在各个学科中，尤其是在人类法医鉴定、亲子鉴定和疾病诊断领域，这些活动已进入商业应用阶段。然而，总体而言，这些领域及其他领域的质量保证严格程度并未跟上分子诊断技术的创新步伐。用于客观且持续评估分子诊断服务质量的资源不足，而持续的质量是该行业长期可信度的关键。这项技术迅速扩张的商业前景，必须伴随着对具有成本效益的质量保证计划进行有计划的资源投入，这些计划包括公开和非公开的试验。
